S&P 500 Rises on Pharmaceutical Deal Despite Disappointing Data

S&P 500 Rises Despite Disappointing Data (Bloomberg) New York-area manufacturing data did not live up to forecasts, but a $25 billion deal by pharmaceutical company Actavis Plc to buy Forest Laboratories buoyed the market. The S&P 500 rose 0.1%, to within eight points of its record close. “Weaker economic numbers have been shrugged off,” Eric […]

  • by:
  • 08/21/2022
ad-image

S&P 500 Rises Despite Disappointing Data (Bloomberg)

New York-area manufacturing data did not live up to forecasts, but a $25 billion deal by pharmaceutical company Actavis Plc to buy Forest Laboratories buoyed the market. The S&P 500 rose 0.1%, to within eight points of its record close. “Weaker economic numbers have been shrugged off,” Eric Green, director of research and fund manager at Philadelphia-based Penn Capital Management, said. “It seems like the consensus view is that weather is a huge issue in the numbers. The outlook looks pretty benign right now. We can probably reach new highs in the near term in the equity markets.”

Image:

Opinion

View All

EXCLUSIVE: Mike Davis warns SCOTUS may rule 7-2 upholding birthright citizenship

“I worry this is a 7-2 case, and I worry that the only two justices who will actually have the courag...

Trump threatens NATO exit over allies' Iran war posture

"Oh yes, I would say (it’s) beyond reconsideration."...

Mexican navy sweeps up 234 suspects, seizes over a TON of meth in nation-wide crackdown

The operations were carried out between March 23 and 29 under Operation Sable, which included 147 sep...

CHRISTIANE EMERY: JK Rowling survived the 'TERF Trials' because fans refused to cancel Harry Potter

Hollywood may continue to navigate the tension between public signaling and private incentives, but i...